SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-19-044881
Filing Date
2019-08-08
Accepted
2019-08-08 16:02:48
Documents
65
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a19-10378_110q.htm 10-Q 1424559
2 EX-31.1 a19-10378_1ex31d1.htm EX-31.1 12578
3 EX-31.2 a19-10378_1ex31d2.htm EX-31.2 12578
4 EX-32.1 a19-10378_1ex32d1.htm EX-32.1 6616
5 EX-32.2 a19-10378_1ex32d2.htm EX-32.2 6948
  Complete submission text file 0001104659-19-044881.txt   6396643

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nbrv-20190630.xml EX-101.INS 1260012
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nbrv-20190630.xsd EX-101.SCH 56880
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nbrv-20190630_cal.xml EX-101.CAL 46235
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nbrv-20190630_def.xml EX-101.DEF 270928
10 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nbrv-20190630_lab.xml EX-101.LAB 504193
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nbrv-20190630_pre.xml EX-101.PRE 430814
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 191009425
SIC: 2834 Pharmaceutical Preparations